about
Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic reviewCharacterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancerEffects of quantum noise in 4D-CT on deformable image registration and derived ventilation data.Optimal gating compared to 3D and 4D PET reconstruction for characterization of lung tumours.Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study.Predicting outcomes in radiation oncology--multifactorial decision support systemsRepeatability of hypoxia PET imaging using [¹⁸F]HX4 in lung and head and neck cancer patients: a prospective multicenter trialResponse assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancerShould patient setup in lung cancer be based on the primary tumor? An analysis of tumor coverage and normal tissue dose using repeated positron emission tomography/computed tomography imaging.Assessment of tumour size in PET/CT lung cancer studies: PET- and CT-based methods compared to pathology.Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion.A literature review of electronic portal imaging for radiotherapy dosimetry.Evaluation of tumour hypoxia during radiotherapy using [18F]HX4 PET imaging and blood biomarkers in patients with head and neck cancer[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging.Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach.State of the art radiation therapy for lung cancer 2012: a glimpse of the future.A novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the "Low Drug Uptake Volume".Validation of dose painting of lung tumours using alanine/EPR dosimetry.PET-based dose painting in non-small cell lung cancer: Comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes.Impact of PET reconstruction algorithm and threshold on dose painting of non-small cell lung cancer.Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT.Quality assessment of positron emission tomography scans: recommendations for future multicentre trials.Feature selection methodology for longitudinal cone-beam CT radiomics.Dual energy CT in radiotherapy: Current applications and future outlook.PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer.Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures.Regional variability in radiation-induced lung damage can be predicted by baseline CT numbers.Improved dose calculation accuracy for low energy brachytherapy by optimizing dual energy CT imaging protocols for noise reduction using sinogram affirmed iterative reconstruction.Accuracy of deformable image registration for contour propagation in adaptive lung radiotherapy.Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation.Evaluation of nonrigid registration models for interfraction dose accumulation in radiotherapy.Clustering of multi-parametric functional imaging to identify high-risk subvolumes in non-small cell lung cancer.Development of a virtual spacer to support the decision for the placement of an implantable rectum spacer for prostate cancer radiotherapy: Comparison of dose, toxicity and cost-effectiveness.Three-dimensional dose evaluation in breast cancer patients to define decision criteria for adaptive radiotherapy.4DCT imaging to assess radiomics feature stability: An investigation for thoracic cancers.Radiomics: the bridge between medical imaging and personalized medicine.Clinical evaluation of atlas and deep learning based automatic contouring for lung cancer.Dual-energy CT quantitative imaging: a comparison study between twin-beam and dual-source CT scanners.The promise of multiparametric imaging in oncology: how do we move forward?
P50
Q26859511-B430CA0B-F378-4EA1-AEC5-B7D010EC9882Q27304358-477EF9DF-F3E5-4229-B389-DEF04208C543Q30674880-1E0611A8-A709-43C0-9570-0EE0212016B3Q34756997-150DED30-A7BB-474D-9F50-682DFA1B2F47Q36014679-F5B8FEE1-6A13-49AF-91C1-3429B2554916Q36014711-14161342-E57E-41FE-ACAB-7F858DDB0E65Q36109283-899DAE6D-A4C0-403A-A5D6-C9F547BCCCEEQ36341962-4205FCF5-DA42-4CDA-BFE4-76A480968569Q36410352-4CA4779C-7FD7-45BD-A32E-EF55068035ABQ36412502-29C74E56-7175-42EB-A482-91D95C1700B4Q36427037-D518BB74-3BF1-42AA-8266-B500C2F3D5E5Q37244942-9C36552D-FD7A-4D48-A67B-E2F999823B7EQ37306472-D1985264-F6D1-46C1-99B2-A526EE892A42Q37433626-0B904D91-FA3D-4A67-9559-55678F631EBBQ37581964-89ED4796-E4F2-4685-88F6-554C90AC5793Q37706118-D43666DB-E3B3-4F36-A038-95A1B82237A6Q38031320-DD0410EA-4340-4045-9C08-8E8993462E10Q38401006-905A64A6-D190-4959-B7E3-B0532C1E289CQ38409529-F79EA7DF-97AF-4528-B4C3-10F4DC512D65Q38413306-C896B491-18A6-4CBA-AEF2-290FCFBFECBAQ38417618-CFF0C8A0-50B2-441E-B1E3-EF75406369A2Q38608607-A4B1B35F-EB3D-4BEF-A9C3-C7A4654BC329Q38638684-EA541D6B-A7E4-48C4-B130-267E144A84CCQ38639487-C80B6077-E042-40EE-A9CE-835FD81CBE7DQ38774117-E94184AB-DD40-4109-89DB-72BD76B362C1Q38778432-255DAB62-841C-421B-BE9E-F29908C8A4CBQ38784854-F098764E-07DF-4322-AE27-AD1CF6AC1C6DQ40423413-C99F895C-276C-4662-B36E-01600AB25D2FQ40482477-9223CFEA-5DC1-44DB-8D9D-115D27B8083FQ42922883-AFF97F86-6436-44E1-9BC0-936C8C9AB87FQ44702085-45C4B43E-ECDD-40BA-B37D-42415DD67FB9Q46079904-3ED78438-5E97-497A-AFC1-8CB743FA678DQ47623098-32B866E8-DAAD-41E0-8E57-D68A33ED226DQ47775904-4970B8A4-D144-4798-A8F8-AA16DB4BE314Q47789964-BA3F880F-344B-4EA8-A2B7-E978481F2522Q47805273-6A58E090-4F6A-4C52-BBEC-25A3B46A357AQ47869134-54948B21-8594-484C-9F06-EF4B58311170Q48580227-78C01120-6F0A-4FE8-AC72-98045115817FQ50462825-D699416D-2CAF-44F5-A6A1-585E9C84160DQ50525080-30E71D00-CDA5-4BE0-9C3C-1B3BFC39DAE0
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Wouter van Elmpt
@ast
Wouter van Elmpt
@en
Wouter van Elmpt
@es
Wouter van Elmpt
@nl
type
label
Wouter van Elmpt
@ast
Wouter van Elmpt
@en
Wouter van Elmpt
@es
Wouter van Elmpt
@nl
prefLabel
Wouter van Elmpt
@ast
Wouter van Elmpt
@en
Wouter van Elmpt
@es
Wouter van Elmpt
@nl
P106
P31
P496
0000-0001-8820-0784